DNA origami vaccine (DoriVac) nanoparticles improve both humoral and cellular immune responses to infectious diseases

Yang C. Zeng,Olivia J. Young,Longlong Si,Min Wen Ku,Giorgia Isinelli,Anjali Rajwar,Amanda Jiang,Chris M. Wintersinger,Amanda R. Graveline,Andyna Vernet,Melinda Sanchez,Ju Hee Ryu,Ick Chan Kwon,Girija Goyal,Donald E. Ingber,William M. Shih

DOI: https://doi.org/10.1101/2023.12.29.573647

2024-01-02

Abstract:Current SARS-CoV-2 vaccines have demonstrated robust induction of neutralizing antibodies and CD4 T cell activation, however CD8 responses are variable, and the duration of immunity and protection against variants are limited. Here we repurposed our DNA origami vaccine platform, DoriVac, for targeting infectious viruses, namely SARS-CoV-2, HIV, and Ebola. The DNA origami nanoparticle, conjugated with infectious-disease-specific HR2 peptides, which act as highly conserved antigens, and CpG adjuvant at precise nanoscale spacing, induced neutralizing antibodies, Th1 CD4 T cells, and CD8 T cells in naïve mice, with significant improvement over a bolus control. Pre-clinical studies using lymph-node-on-a-chip systems validated that DoriVac, when conjugated with antigenic peptides or proteins, induced promising cellular immune responses in human cells. These results suggest that DoriVac holds potential as a versatile, modular vaccine platform, capable of inducing both humoral and cellular immunities. The programmability of this platform underscores its potential utility in addressing future pandemics.

Immunology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is that the current SARS - CoV - 2 vaccines are insufficient in inducing CD8+ T - cell responses and have a limited duration of immune protection against virus variants. By re - using their previously developed DNA origami vaccine platform (DoriVac), the researchers aim to improve the quality and durability of humoral and cellular immune responses against infectious diseases including SARS - CoV - 2, HIV and Ebola.

Specifically, the objectives of the paper include:
1. **Enhancing the breadth and intensity of immune responses**: By using the highly conserved HR2 peptide as an antigen and combining it with CpG adjuvant, which are fixed on DNA origami nanoparticles at precise nanoscale spacing, thereby enhancing the production of neutralizing antibodies and simultaneously activating Th1 - type CD4+ T - cells and CD8+ T - cells.
2. **Verifying the versatility and programmability of the DoriVac platform**: Demonstrating that the DoriVac platform can be adapted to vaccine designs for multiple infectious diseases, especially by connecting the HR2 peptides of specific pathogens to DNA origami to achieve effective immune responses against different pathogens.
3. **Evaluating the immune effects of DoriVac in human cells**: Conducting pre - clinical studies using the lymph node - on - a - chip system to verify the cellular immune responses induced by DoriVac in human cells, especially the activation in human monocyte - derived dendritic cells (DCs).

In summary, this study aims to overcome the limitations of existing vaccines in dealing with virus variants and long - term immune protection by improving vaccine design and providing a more effective and versatile vaccine platform.